U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07296484) titled 'Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)' on Nov. 30.
Brief Summary: CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
Study Start Date: Dec. 31
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes
Cortisol Excess
Intervention:
DRUG: clofutriben
HSD-1 inhibitor
DRUG: Pla...